{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05919329",
            "orgStudyIdInfo": {
                "id": "STUDY00025799"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2023-06184",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                }
            ],
            "organization": {
                "fullName": "OHSU Knight Cancer Institute",
                "class": "OTHER"
            },
            "briefTitle": "Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy",
            "officialTitle": "Modulation of PSMA Expression in Castration Sensitive and Castration Resistant Prostate Cancer in Response to Hormonal Therapy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "evaluation-of-the-change-in-psma-expression-in-prostate-cancer-in-response-to-hormonal-therapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-09-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-09-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-06-16",
            "studyFirstSubmitQcDate": "2023-06-16",
            "studyFirstPostDateStruct": {
                "date": "2023-06-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Nadine Mallak, MD",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "OHSU Knight Cancer Institute"
            },
            "leadSponsor": {
                "name": "OHSU Knight Cancer Institute",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Oregon Health and Science University",
                    "class": "OTHER"
                },
                {
                    "name": "Progenics Pharmaceuticals, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy.",
            "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. To determine the early effects (at day 8) of hormonal therapy on PSMA modulation in patients with castration sensitive prostate cancer (CSPC) and castration resistant prostate cancer (CRPC)\n\nSECONDARY OBJECTIVES:\n\nI. To evaluate the effects of hormonal therapy on PSMA modulation at day 28 post-therapy in patients with CSPC and CRPC\n\nII. To evaluate whether the change in PSMA modulation after hormonal therapy initiation changes the tumor staging on PSMA PET as defined by the PROMISE V2 criteria.\n\nEXPLORATORY OBJECTIVES:\n\nI. To assess whether the initial change in PSMA modulation in response to hormonal therapy holds prognostic implications\n\nII. To assess for potential correlation between the early change in PSMA modulation and tumor characteristics such as Gleason score, and site of disease.\n\nIII. To assess whether the baseline level of PSMA uptake holds prognostic implications in response to hormonal therapy\n\nOUTLINE:\n\nPatients will be divided (non-randomized) into 2 groups (CRPC or CSPC) and receive PSMA PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.\n\nParticipants will be followed for up to 5 years."
        },
        "conditionsModule": {
            "conditions": [
                "Castration Resistant Prostate Cancer",
                "Castration Sensitive Prostate Cancer",
                "Prostate Adenocarcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: CRPC",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with CRPC will receive 18F-DCFPyL PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.",
                    "interventionNames": [
                        "Drug: Piflufolastat",
                        "Procedure: PSMA PET/CT Scan",
                        "Procedure: PSMA PET/MRI scan",
                        "Procedure: Biospecimen Collection",
                        "Other: Electronic Health Record Review"
                    ]
                },
                {
                    "label": "Cohort 2: CSPC",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with CSPC will receive 18F-DCFPyL PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.",
                    "interventionNames": [
                        "Drug: Piflufolastat",
                        "Procedure: PSMA PET/CT Scan",
                        "Procedure: PSMA PET/MRI scan",
                        "Procedure: Biospecimen Collection",
                        "Other: Electronic Health Record Review"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Piflufolastat",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Cohort 1: CRPC",
                        "Cohort 2: CSPC"
                    ],
                    "otherNames": [
                        "Piflufolastat F-18",
                        "Pylarify",
                        "18F-DCFPyL",
                        "Fluorine F 18 DCFPyL"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "PSMA PET/CT Scan",
                    "description": "Undergo PSMA PET/CT",
                    "armGroupLabels": [
                        "Cohort 1: CRPC",
                        "Cohort 2: CSPC"
                    ],
                    "otherNames": [
                        "Prostate-Specific Membrane Antigen PET/CT",
                        "PSMA PET/CT",
                        "PSMA-Positron emission tomography/CT"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "PSMA PET/MRI scan",
                    "description": "Undergo PET/MRI",
                    "armGroupLabels": [
                        "Cohort 1: CRPC",
                        "Cohort 2: CSPC"
                    ],
                    "otherNames": [
                        "Prostate-Specific Membrane Antigen PET/MRI",
                        "PSMA PET/MR",
                        "PSMA-Positron emission tomography/magnetic resonance imaging"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Biospecimen Collection",
                    "description": "Undergo collection of blood samples",
                    "armGroupLabels": [
                        "Cohort 1: CRPC",
                        "Cohort 2: CSPC"
                    ],
                    "otherNames": [
                        "Biological Sample Collection",
                        "Specimen Collection",
                        "Lab draw"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Electronic Health Record Review",
                    "description": "Ancillary studies",
                    "armGroupLabels": [
                        "Cohort 1: CRPC",
                        "Cohort 2: CSPC"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in maximum standardized uptake value (SUVmax) on post-therapy initiation PSMA PET (8 \u00b1 2 days) compared to baseline.",
                    "description": "Evaluate the change in SUVmax between baseline and Day 8 using a paired t-test to determine how hormonal therapy affects the PSMA modulation.",
                    "timeFrame": "Baseline PSMA PET up to 8 days after therapy initiation"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in SUVmax on post-therapy initiation PSMA PET (28 \u00b1 3 days) compared to baseline.",
                    "description": "Evaluate the change in SUVmax between baseline and Day 28 using a paired t-test to determine how hormonal therapy affects the PSMA modulation.",
                    "timeFrame": "Baseline PSMA PET up to 28 days after therapy initiation"
                },
                {
                    "measure": "Number of patients in whom the tumor staging changed on PSMA PET scans obtained post-therapy initiation relative to baseline PET scan",
                    "timeFrame": "Baseline PSMA PET up to 28 days after therapy initiation"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant or legally authorized representative (LAR) must provide written informed consent before any study-specific procedures or interventions are performed.\n* Participants must have histologically confirmed prostate adenocarcinoma.\n* Age \\>= 18 years. Given the nature of the disease in question, only men will be included. Members of all races and ethnic groups will be included.\n* Participants must have sites of prostate cancer showing uptake on an initial PSMA PET scan.\n* Participants are planned to receive hormonal therapy within four weeks of the initial PSMA PET.\n* Life expectancy \\> 3 months.\n* Cohort 1: Castration resistant prostate cancer with rising PSA (confirmed by two PSA values at least 1 week apart), testosterone \\< 50 ng/dL, on continuous ADT at least 4 months, no AR targeted agent in the prior 4 months.\n* Cohort 2: Castration sensitive prostate cancer with no ADT or AR targeted agents use in the past 12 months, testosterone \\>50 ng/dL\n\nExclusion Criteria:\n\n* Uncontrolled serious infection.\n* Intercurrent illness or condition that would limit compliance with study requirements.\n* Participants who have undergone any cancer treatment other than the hormonal therapy (systemic or radiation therapy) or who have started any supplements or herbal medications intended to treat cancer between the baseline PSMA PET and PSMA PET at day 28.",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lauren Drake",
                    "role": "CONTACT",
                    "phone": "503-494-4960",
                    "email": "RADResearch@ohsu.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Nadine Mallak, MD",
                    "affiliation": "OHSU Knight Cancer Institute",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "OHSU Knight Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lauren Drake",
                            "role": "CONTACT",
                            "phone": "503-494-4960",
                            "email": "RADResearch@ohsu.edu"
                        },
                        {
                            "name": "Nadine Mallak, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                },
                {
                    "id": "D000006967",
                    "term": "Hypersensitivity"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "asFound": "Sensitive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M8587",
                    "name": "Fluorides",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}